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Background: Fusion genes have been recognized to play key roles in oncogenesis. Though, many techniques have
been developed for genome-wide analysis of fusion genes, a more efficient method is desired.
Results: We introduced a new method of detecting the novel fusion gene by using GeneChip Exon Array that
enables exon expression analysis on a whole-genome scale and TAIL-PCR. To screen genes with abnormal exon
expression profiles, we developed computational program, and confirmed that the program was able to search the
fusion partner gene using Exon Array data of T-cell acute lymphocytic leukemia (T-ALL) cell lines. It was reported
that the T-ALL cell lines, ALL-SIL, BE13 and LOUCY, harbored the fusion gene NUP214-ABL1, NUP214-ABL1 and
SET-NUP214, respectively. The program extracted the candidate genes with abnormal exon expression profiles: 1
gene in ALL-SIL, 1 gene in BE13, and 2 genes in LOUCY. The known fusion partner gene NUP214 was included in
the genes in ALL-SIL and LOUCY. Thus, we applied the proposed program to the detection of fusion partner genes
in other tumors. To discover novel fusion genes, we examined 24 breast cancer cell lines and 20 pancreatic cancer
cell lines by using the program. As a result, 20 and 23 candidate genes were obtained for the breast and pancreatic
cancer cell lines respectively, and seven genes were selected as the final candidate gene based on information of
the EST data base, comparison with normal cell samples and visual inspection of Exon expression profile. Finding of
fusion partners for the final candidate genes was tried by TAIL-PCR, and three novel fusion genes were identified.
Conclusions: The usefulness of our detection method was confirmed. Using this method for more samples, it is
thought that fusion genes can be identified.
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It is well known that cancer is caused by gene abnormal-
ities. There are many types of abnormalities in the genome
of cancer cells, including gene fusion because of chromo-
some rearrangement. The discovery of a characteristic small
chromosome, called Philadelphia chromosome, in chronic
myeloid leukemia, is the first recurrent chromosome re-
arrangement to be seen in a human cancer [1]. This re-
arrangement was eventually identified as a translocation
between chromosome 9 and 22 [2], resulting in the fusion
of the BCR gene on chromosome 22 with the ABL1 gene* Correspondence: ywada@fasmac.co.jp
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reproduction in any medium, provided the oron chromosome 9, BCR-ABL1 [3]. Because many chromo-
somal abnormalities and fusion genes have been discovered
by the development of experimental techniques, it has been
shown that such fusion genes and chromosomal abnormal-
ities are causes of cancer. Thus, the importance of chromo-
somal abnormalities and fusion genes in cancer has been
recognized.
It is also known that fusion genes have a key role in onco-
genesis in hematological tumors and sarcomas. Since fusion
genes are closely related to the clinical and pathological fea-
tures of tumors, they provide important clues for diagnosis.
In addition, fusion genes are regarded as attractive targets
of molecular targeted treatments because of their high spe-
cificity to tumors.
So far, fusion genes have been found less frequently in
common solid cancers, but some reports on prostate [4]
and lung carcinomas [5] show that fusion genes contributetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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It is predicted that fusion genes have important roles in
many other kinds of epithelial tumors [6]. In late years,
various fusion genes came to be discovered by many kinds
of cancers [7].
Although many technologies are used for the genome-
wide screening of fusion genes, there are not yet any versa-
tile methods. Karyotyping requires the availability of fresh,
vital cells for short-term culturing to obtain metaphase
chromosomes, and it has low resolution. Array comparative
genomic hybridization (array CGH) cannot detect fusion
genes without genomic copy number change [8]. Recent
developments of high-throughput sequencing technologies
provide a powerful tool [9-12]. But these technologies are
as yet limited by the number of samples that can be ana-
lyzed at acceptable cost.
Affymetrix GeneChip Human Exon 1.0 ST Array (Exon
Array) is a whole-genome exon expression analysis tool.
About 5.5 million probes are being designed on the array,
and they compose about 1.4 million probe sets (in principle,
the probe set is composed of four probes, and one expres-
sion intensity is calculated from one probe set). The expres-
sion of almost all exons can be analyzed using the Exon
Array, and it enables genome-wide alternative splicing
analysis. Each probe set has an ID, and belongs to a tran-
script cluster that corresponds to a gene. Annotations are
given to the probe sets, and are available to the public at
Affymetrix NetAffx (http://www.affymetrix.com/analysis/
index.affx). The probe sets are classified into three evidence
levels according to the quality of evidence supporting the
transcription of the target genomic sequence. The three
evidence levels are presented in decreasing order of confi-
dence: “core” (RefSeq and full-length mRNAs), “extended”
(ESTs, syntenic rat and mouse mRNAs) and “full” (ab-initio
computational predictions). Simultaneously, the probe sets
are annotated with hybridization targets that describe
cross-hybridization potential. The hybridization targets
are shown in decreasing order of uniqueness: “unique”,
“mixed”, and “similar”.
In this report, a method to detect abnormal gene struc-
tures, including gene fusion, was developed using Exon
Array. Using this methodology and TAIL-PCR, novel fusion
genes were discovered in breast and pancreatic cancer cell
lines. Breast cancer is a heterogeneous disease encompass-
ing a wide variety of pathological features and a range of
clinical behavior [13]. These are underpinned at the mo-
lecular level by complex components of genetic alterations
that affect cellular processes [14]. Therefore, it is possible to
contribute for understanding of the heterogeneity and diag-
nosis with high accuracy by discovering novel fusion genes.
Pancreatic cancer is a highly aggressive tumor with no
proven curative chemotherapy or radiation therapy, having
extremely poor prognosis [15]. The discovery of a fusion
gene in pancreatic cancer can lead to molecular targettherapy, with the possibility of offering an effective treat-
ment method for pancreatic cancer.
Methods
Samples
Twenty-four breast cancer cell lines (AU565, BT474,
DU4475, HCC38, HCC70, HCC202, HCC1143, HCC1187,
HCC1419, HCC1428, HCC1569, HCC1806, HCC1954,
MCF7, MDA-MB-157, MDA-MB-231, MDA-MB-330,
MDA-MB-361, MDA-MB-435S, MDAMB-468, SK-BR-3,
UACC812, UACC893, ZR-75-1) were obtained from
American Type Culture Collection (ATCC), and main-
tained in under the conditions recommended by the sup-
plier. Twenty pancreatic cancer cell lines (MA005, MA006,
PA018, PA022, PA028, PA043, PA051, PA055, PA086,
PA090, PA103, PA107, PA109, PA167, PA173, PA182,
PA195, PA199, PA202, PA215) were established at Genome
Center, Japanese Foundation for Cancer Research (JFCR).
Two vials of normal mammary epithelial cells (HMEC),
which were donated from different subjects, were obtained
from Takara Bio Inc. A non-tumorigenic human breast epi-
thelial cell line (MCF10A) was obtained from ATCC. These
were maintained using TaKaRa MEGM BulletKit (Takara
Bio Inc, Otsu, Japan) according to the manufacturer’s in-
structions. A clear cell sarcoma cell line “SarcomaA” was
provided by Dr. Nakamura at Cancer Institute, JFCR.
Samples of tumor tissues were obtained from a series
of patients with breast or pancreatic cancer who under-
went surgery at the JFCR Hospital. All samples were
snap-frozen in liquid nitrogen within 1 h after surgery
and stored at −80˚C. Before RNA was prepared, laser-
captured microdissection (LCM) using a Leica Microsys-
tems AS LMD 600 (Leica Microsystems, Wetzlar,
Germany) was performed to ensure that only tumor cells
were dissected. LCM was conducted in all tumor
samples.
Open access exon array data
Exon Array CEL files of 17 T-cell acute lymphocytic
leukemia (T-ALL) cell lines (ALL-SIL, BE13, CEM, DND41,
DU528, JURKAT, KOPTK1, LOUCY, MOLT13, MOLT16,
MOLT4, PF382, RPMI8402, SUPT11, SUPT13, SUPT7,
TALL1) were obtained from NCBI Gene Expression
Omnibus database (Series GSE9342, http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE9342). It was re-
ported that ALL-SIL, BE13 and LOUCY harbored fusion
genes NUP214-ABL1, NUP214-ABL1, and SET-NUP214,
respectively [16,17].
Total RNA extraction and cDNA synthesis
Total RNA was extracted from the cells or the tissues by
RNeasy Mini Kit according to the manufacturer’s in-
structions (Qiagen, Valencia, CA). 1 μg of total RNA was
reverse transcribed to synthesize template cDNA by a
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Strand Synthesis System(Life Technologies, Carlsbad,
California), and 20 μl synthesized cDNA was diluted 500
times with Tris/HCl buffer.
Exon array experiment
Exon Array data was generated according to the manufac-
turer’s instructions. Ribosomal RNA was removed from
1 μg of total RNA using Invitrogen RiboMinu Transcrip-
tome Isolation Kit, and amplified cDNA was synthesized
using GeneChip WT cDNA Synthesis and Amplification
Kit. To make hybridization probes, amplified cDNA was
fragmented and biotin-labeled using GeneChip WT Ter-
minal Labeling Kit. The hybridization probes were hybrid-
ized to GeneChip Human Exon 1.0 ST Array at 45°C in a
hybridization oven at 60 rpm for 16 h, and washed in Fluid-
ics Station 450 using GeneChip Hybridization Wash, and
Stain Kit. The array was scanned on GeneChip Scanner
3000 7G. To implement signal summarization, expression
intensities for the “core” ProbeSet were calculated using lin-
ear normalization and the average-difference method from
Affymetrix Power Tools. The median intensity of all arrays
was adjusted linearly to 100.
Fusion gene screening program
The program was developed to detect fusion genes with
an exon expression profile similar to that of EWSR1 and
ATF1 in a clear cell sarcoma cell line, SarcomaA. Details
of the program are shown in 1–8
1. To exclude the influence of non-specific
hybridization, only probe sets with Hybridization
Target “unique” were used.
2. To exclude probe sets that showed extremely low
signal intensities in all samples, only probe sets with 30
or higher signal intensity in at least one sample were
used.
3. To use probe sets corresponding to known exon
sequence, only probe sets with Evidence Level
“Core” were used.
4. To avoid the influence of alternative splicing and non-
specific hybridization, 5–8 were performed for probe
sets of the Transcript Cluster with 8 or more probe sets
for which conditions 1–3 were met.
5. To compare expression levels among probe sets in
each sample, the rank of each probe set of the
sample was decided based on the signal intensity.
6. One transcript cluster with probe sets for which
conditions 1–3 were met were separated into 5′
and 3′ terminal groups at all possible cut off
points so that each terminal group contains 4 or
more probe set. (“cut off point” is only used in
our algorithm to divide genome region into 5′ or
3′ terminal groups) For each sample, the averagerank of probe sets in 5′ and 3′ terminal groups
were calculated, respectively.
7. To detect genes with a clear expression level change
before and behind the cut off points, it is confirmed
that the difference in the average ranks of 5′ and 3′
terminal groups was 70% or more of the number of
samples.
8. To reduce the possibility of false positives by
measurement errors, the cut off points were
identified as breakpoints only when at least one of
the standard deviations of probe set ranks in 5′ or 3′
terminal groups was 2.0 or lower. Transcript
clusters with candidate breakpoints were identified
as candidate genes.
Our program for detecting fusion genes was written in
Fortran95. One more program for drawing exon expres-
sion pattern of samples and location of exon in the gen-
ome database, as shown in the figures in this paper, was
written in statistical language of R. We used Windows
PC for both programs as a platform. Any machines in-
stalled with the Fortran95 and R would be able to be
used for our purpose. Our source program will be avail-
able on direct request to the corresponding author.
Evaluation of candidate genes
To take transcript isoforms of candidate genes into con-
sideration, the transcript isoform information registered
in UCSC Genome Browser (http://genome.ucsc.edu/cgi-
bin/hgGateway) “UCSC Gene” and “Ensembl Gene Pre-
diction” was used. When the exon/intron structure of
the aberrant transcript predicted from the exon expres-
sion profile of the candidate gene was similar to the reg-
istered transcript isoform, the gene was excluded from
candidate genes. When the candidate gene (Transcript
Cluster) corresponds to two or more RefSeq genes in
UCSC Genome Browser, the gene was also excluded
from candidate genes. When the exon expression profile
of the screened sample in candidate genes was similar to
the profile of the reference sample, the gene was ex-
cluded from candidate genes. Moreover, exon expression
profiles of the candidate genes were evaluated by visual
inspection in detail.
TAIL-PCR, RT-PCR and one step RT-PCR
TAIL-PCR (thermal asymmetric interlaced-PCR) was
performed with a slight modification of the original
Yao-Guang Liu and Yuanling Chen’s high-efficiency TAIL-
PCR protocol [18] for the identification of fusion counter-
part. The primers and thermal cycling condition are
shown in Tables 1, 2, and 3. For RT-PCR, TaKaRa Ex Taq
Hot Start Version and 2 μl synthesized cDNA as template
were used. Thermal cycling was carried out under the fol-
lowing conditions: 1 min at 95°C followed by 35 cycles of
Table 1 Gene-specific primers for TAIL-PCR
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pairs used in this experiment were designed to make the
amplification product including the breakpoints of the fu-
sion genes. For One Step RT-PCR, TaKaRa One Step
SYBR PrimeScript RT-PCR Kit II was used according toTable 2 LAD primers and AC1 primer for TAIL-PCR











AC1 ACGATGGACTCCAGAGthe manufacturer’s instructions. 1 ng of total RNA from
the dissected tumor cells was used as a template in each
20 μl reaction. Thermal cycling was carried out under the
following conditions: 30 min at 50°C, 2 min at 94°C
followed by 35 cycles of 30 sec at 94°C, 30 sec at 65°C,
1 min at 72°C. The primers for RT-PCR and One step RT-
PCR are shown in Table 4.
The amplified PCR products were electrophoresed on
1.0% or 2.0% agarose gels, and were purified using GL
Sciences MonoFas DNA purification kit I (GL Sciences,
Tokyo, Japan). The purified products were sequenced using
Applied Biosystems BigDye Terminator v3.1 Cycle Sequen-
cing Kit (Life Technologies, Carlsbad, California), and the
reaction products were purified using Promega Wizard
MagneSil Sequencing Reaction Clean-Up System (Promega,
Madison, WI). The purified samples were analyzed using
Applied Biosystems 3130χ Genetic Analyzer.
Results
Development of fusion gene screening program
To profile the exon expression in fusion genes, Sarco-
maA which harbors the fusion gene EWSR1-ATF1, was
used for Exon Array experiments (Figure 1). Exon ex-
pression profiles of EWSR1 and ATF1 were characterized
(Figure 2), and the following features were observed.
1: Probe sets in the exon region had high signal inten-
sity, and probe sets in the intron region had low signal
intensity. 2: In some probe sets, all samples had equiva-
lent signal intensity. In other probe sets, all samples had
extremely low equivalence. 3: The expression signals
vary in each probe set on a gene of one sample. 4: Sarco-
maA showed a change in the expression level at the
breakpoint in comparison with breast cancer cell lines.
Then the fusion gene screening program was devel-
oped to detect fusion genes with an exon expression
profile similar to that of EWSR1 and ATF1.
The detection performance of the developed program
was examined using the Exon Array data of the T-ALL
cell lines. The program selected the candidate genes:
one gene in ALL-SIL, one gene in BE13, and two genes
in LOUCY. NUP214, the partner gene of the known fu-
sion genes, was detected in ALL-SIL and LOUCY. Other
known fusion partner genes, ABL1 in ALL-SIL, NUP214
and ABL1 in BE13, SET in LOUCY, were not detected
in this case, because the probe sets that could be used in
the 5′ or 3′ terminal groups were three or less. Al-
though the NUP214 gene was detected as a candidate
gene in ALL-SIL and LOUCY, its exon expression profile
was different between the two cell lines. While the ex-
pression decreases from the 5′ terminal side to the 3′
terminal side at the breakpoint in ALL-SIL, it was op-
posite in LOUCY. Thus it was confirmed that gene de-
tection by the program did not depend on the direction
of the expression change. Although breakpoints were
Table 3 Thermal conditions for TAIL-PCR
Pre-amplification Primary TAIL-PCR Secondary TAIL-PCR
Step Temperature (°C) Time (min:sec) Step Temperature (°C) Time (min:sec) Step Temperature (°C) Time (min:sec)
1 93 2:00 1 94 0:20 1 94 0:20
2 95 1:00 2 65 1:00 2 68 1:00
3 94 0:30 3 72 3:00 3 72 3:00
4 25 2:00 4 To step 1 1 time 4 94 0:20
5 Ramping to 72 0.5°C/s 5 94 0:20 5 68 1:00
6 72 3:00 6 68 1:00 6 72 3:00
7 94 0:30 7 72 3:00 7 94 0:20
8 60 1:00 8 94 0:20 8 50 1:00
9 72 3:00 9 68 1:00 9 72 3:00
10 Go to step7 10 times 10 72 3:00 10 To step 1 7 times
11 94 0:30 11 94 0:20 11 72 5:00
12 25 2:00 12 50 1:00
13 Ramping to 72 0.5°C/s 13 72 3:00
14 72 3:00 14 To step 5 13 times
15 94 0:20 15 72 5:00
16 58 1:00
17 72 3:00
18 Go to step 15 25 times
19 72 5:00
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they corresponded to the position of reported break-
points. It was confirmed that the breakpoint was de-
tected accurately by the program (Figure 3).
Candidate genes in breast and pancreatic cancer cell lines
To discover the novel fusion gene in breast and pancre-
atic cancer cell lines, candidate genes were selected by
the proposed methodology. As a result, 20 genes wereTable 4 Primers for RT-PCR












ZMPSTE24-exon10 Reverseselected in 24 breast cancer cell lines. Four of the se-
lected genes were excluded from the candidates, because
it was thought that the exon expression profiles of these
4 genes were influenced by known transcript isoforms.
One gene was excluded, because a similar exon expres-
sion profile to the cancer cell line detected by the pro-
gram was also observed in HMEC. As a result of the
evaluation of the 15 remaining genes, 4 most attractive













Figure 1 Schema of EWSR1-ATF1 mRNA. EWSR1 exon 1-10 fuse to ATF1 exon 5-7 by in-frame. Boxes with numbers represent the exon regions
of the genes.
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23 genes were selected by the program. Nine genes of
them thought to be influenced by known transcript iso-
forms, and 3 genes that correspond to two or more
RefSeq genes, respectively, were excluded from the candi-
date genes. As a result of evaluating the 11 remaining
genes, the 3 most attractive genes were selected as candi-
date genes in the pancreatic cancer cell lines. Details are
shown in Table 5 and Figures 3, 4, 5, 6, 7, 8, 9 and 10.
Exon expression profiles of all selected gene by the pro-
gram are shown in Additional file 1 and Additional file 2.
Identification of novel fusion gene
It was attempted to identify unknown counterpart genes
using TAIL-PCR from higher expression ends of selected
candidate genes. In this research we did not carry out it
from lower ends. TAIL-PCR is one of the methods by
which an unknown sequence adjacent to an already-known
sequence can be efficiently amplified [19]. As a result of fu-
sion gene identification experiments for the 7 candidate
genes, gene fusion fragments were acquired for 3 candidate
genes. Additionally, the frequency of fusion genes evaluated
in cell lines and clinical tissue samples using RT-PCR and
One Step RT-PCR.
DOCK5-CDCA2
The upstream sequence of exon 14 of CDCA2 gene
(ENST00000380665) was acquired in breast cancer cell line
UACC893. This sequence was part of the exon 1 of DOCK5
gene (ENST00000276440) (Figure 11A). In addition, the fu-
sion of DOCK 5 exon 1 and CDCA2 exon 14 was con-
firmed by RT-PCR (Figure 11B). But DOCK5-CDCA2
fusion mRNA was not detected by RT-PCR in 111 breast
cancer clinical tissues.
ZMYND8-CEP250
The upstream sequence of exon 22 of CEP250 gene
(ENST00000356095) was searched for in breast cancer cellline BT474, and was found to be a sequence from exon
16 to exon 19 of ZMYND8 gene (ENST00000360911)
(Figure 12A). The fusion of ZMYND8 exon 19 and CEP250
exon 22 was confirmed by RT-PCR (Figure 12B). But
ZMYND8-CEP250 fusion mRNA was not detected by RT-
PCR in 111 breast cancer clinical tissues.
RLF-ZMPSTE24
The upstream sequence of exon 5 of RLF gene
(ENST00000372771) was acquired in pancreatic can-
cer cell line PA043, and was found to be a sequence
from exon 2 to part of exon 5 of ZMPSTE24 gene
(ENST00000372759) (Figure 13A). In addition, the fu-
sion of RLF exon 5 and ZMPSTE24 exon 2 was con-
firmed by RT-PCR (Figure 13B). RLF-ZMPSTE24
fusion mRNA was detected by RT-PCR in pancreatic can-
cer clinical tissue, PA043T (Figure 13C). This tissue was
the origin of the cell line PA043 where RLF-ZMPSTE24
was first identified. The frequency of RLF-ZMPSTE24 ex-
pression in pancreatic cancer patients was 1/58 (1.7%).
Discussion
Here, a method is proposed to detect novel fusion genes
using exon array data of tumor samples in combination
with a new computational program.
Development of new fusion gene detection program
This computational program is based on the following
ideas.
Selection of probe set:
Although a large number of probe sets are designed on
Exon Array, it is known that there are some non-
functional probes. Technical anomalies may give a false
signal for un-functional probe sets due to cross-
hybridization, saturation or an inherently weak and non-
linear response. Actually, some probe sets for EWSR1
and ATF1 were thought to be un-functional probes. To
BA
Figure 2 Exon Array data of fusion partner genes. Exon expression profiles of fusion partner genes EWSR1 (A) and ATF1 (B) are shown by
line graphs with target areas of probe sets and genomic DNA structures. SarcomaA cell line and reference samples (breast cancer cell lines) are
indicated by red and pink lines, respectively. Known breakpoints are shown by blue lines. Characters at top and bottom of probe set numbers
indicate annotations: C = core, e = extended, f = full, U = unique, S = similar, M = mixed.
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probes were removed in step 1, 2, and 3 of the computa-
tional program.
Comparison of expression on different probe sets:
Chromosome rearrangements often lead to the altered
expression of 5′ or 3′ terminal regions of fusion partner
genes by exchange of the transcriptional regulatory
elements. The detection of sudden changes in the
expression level between neighboring probe sets led to
the discovery of breakpoints of fusion genes; however,the signal intensities obtained from different probes
cannot be compared directly. Amplification and labeling
efficiency are different in each RNA region. The
hybridization property of probe sets on the array is also
different in each probe set. Because of these biases, the
signal intensity and dynamic range differ greatly between
probe sets. Each probe set in the same gene has markedly
different signal intensity; therefore, a normalizing method
is needed to compare the signal intensities generated
from different probe sets. On the other hand, signal in-
tensities from different samples on the same probe sets
AB
Figure 3 Expression profiles of NUP214. Exon expression profiles of NUP214 (ENST00000359428) are shown by line graphs with target
areas of probe sets and genomic DNA structures. Examined cell line, (A): ALL-SIL (B): LOUCY, and reference samples (16 T-ALL cell lines) are
indicated by red and pink lines, respectively. Predicted breakpoints are shown by blue lines. Characters at top and bottom of probe set numbers
indicate annotations: C = core, U = unique, S = similar, M = mixed.
Wada et al. Journal of Clinical Bioinformatics 2014, 4:3 Page 8 of 17
http://www.jclinbioinformatics.com/content/4/1/3can be compared because the biases are the same for all
samples. In the program, samples were ranked using the
signal intensities for each probe set in a gene. The change
in rank of a sample implies intragenic exon expression
change.
Grouping and average calculation of probe sets:
Many genes have alternative transcript isoforms in vivo. Al-
ternative splicing may contribute to expression differences
between neighboring exons (probe sets), leading to a rank
change. Moreover, because hybridization reactions on agreat number of probes were performed under only one ex-
perimental condition in microarray experiments, non-
specific cross hybridization cannot be avoided completely.
The generated non-specific signals may influence the rank.
Thus, rank changes between neighboring probe sets are
thought to be observed frequently, and make it difficult to
find the breakpoint. In the developed program, probe sets
in the gene were divided into 5′ and 3′ terminal groups,
and the average ranks of the probe set in each group were
compared. The influences of unexpected rank changes were
mitigated by this process.






sampleUpstream probe set ID Downstream probe set ID
Breast 3075381 ATP6V0A4 3075407 3075406 DU4475
3090697 cDcA2 3090726 3090727 UACCS93
3883309 C’EP250 3883348 3883349 BT474
3892812 SLCO4AJ 3892835 3892837 MDA-MB-231
Pancreas 3521174 ABCC4 3521233 3521248 MA005
2331505 MACF1 2331398 2331419 MA028
2331771 RLF 2331793 2331801 PA043
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determination error margin:
When the gene expression level is similar between sam-
ples, rank changes might take place at random due to
quantitative determination error margins in Exon Array
data, influencing the detection of breakpoints. False detec-
tion was decreased by monitoring the decentralization of a
sample’s rank.
The main feature of the program is that expression
levels between probe sets can be compared by re-
placing the expression signal intensity with the rank.
In general, expression levels were not compared between
probe sets in gene or exon expression analysis by micro-
array. In this research, the developed program and evalu-
ation of candidates chose seven candidate genes, and threeFigure 4 Exon expression profiles of candidate gene ATP6V0A4 in DUnovel fusion genes were identified by TAIL-PCR and RT-
PCR; therefore, it is thought that the proposed method is
very efficient for fusion gene discovery.
There existed fusion gene detection methods through
transcript analysis by microarrays before. However,
these methods were restrictive ones for confirmation of
known fusion gene or for detecting some known partner
genes [20-23].
The detection method for novel fusion genes using
Exon Array has been reported by Eva Lin, in addition to
this research [24]. Lin et al. detected intragenic expres-
sion changes of the ALK gene in lung, breast, and colon
cancer. Based on their results, fusion gene EML4-ALK
was identified using 5′RACE (rapid amplification cDNA
end). Although fusion gene EML4-ALK was originally4475 cell.
Figure 5 Exon expression profiles of candidate gene CDCA2 in UACC893 cell.
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other cancers before their study. Their methods also de-
tect the expression level change between 5′ and 3′ ter-
minal groups of a gene for fusion gene discovery as well
as this report. To compare the expression level betweenFigure 6 Exon expression profiles of candidate gene CEP250 in BT474probe sets, they developed the following method. First,
the mean value and standard deviation of the signal
value of each probe set were calculated for all samples.
Signal intensity was then standardized by subtracting
its mean and dividing by its standard deviation. Thecell.
Figure 7 Exon expression profiles of candidate gene SLCO4A1 in MDA-MB-231 cell.
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sion level of each probe set. The probe sets were then
separated in a transcript cluster into 5′ and 3′ terminal
groups by one arbitrary point, and the expression level
change was monitored between groups by t-test.Figure 8 Exon expression profiles of candidate gene ABCC4 in MA005Comparing the proposed methodology with Lin’s
method, a common feature is that signal intensity is
normalized based on the relative relation to reference
samples, aiming to compare the expression levels of all
probe sets in a gene. The most important difference iscell.
Figure 9 Exon expression profiles of candidate gene MACF1 in PA028 cell.
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that normalized values have a fixed quantity, which is an
advantage to evaluate whether the magnitude of the
change is significant; however, this is influenced easily
by outlier intensities, which are generated frequently inFigure 10 Exon expression profiles of candidate gene RLF in PA043 cmicroarray experiments. On the other hand, in the devel-
oped program, the magnitude of the change is not evalu-
ated appropriately, but it has the advantage that the
result is not influenced easily by the outlier value because
the expression intensity is converted into the rank.ell.
BA
Figure 11 TAIL-PCR detection and RT-PCR confirmation of fusion gene DOCK5-CDCA2. Acquired fusion fragments by TAIL-PCR and exon
structures of fusion partners are shown in (A) Red blocks are exons of candidate gene, blue blocks are exons of detected genes by TAIL-PCR.
Arrows are primers for RT-PCR. RT-PCR confirmations for indicated samples are shown in (B) F: forward primer, R: reverse primer, *: detected
samples in the program.
Figure 12 TAIL-PCR detection and RT-PCR confirmation of fusion gene ZMYND8- CEP250. Acquired fusion fragments by TAIL-PCR and exon
structures of fusion partners are shown in (A) and (B) like Figure 11.




Figure 13 TAIL-PCR detection and RT-PCR confirmation of fusion gene RLFZMPSTE24. Acquired fusion fragments by TAIL-PCR and exon
structures of fusion partners are shown in (A) and (B) like Figure 11, and RT-PCR detections for pancreatic cancer clinical tissue PA043T is shown
in (C).
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The analysis result would possibly change depending on
the selection of reference samples, because signal inten-
sities are converted into relative values by comparing
with other samples. Lin’s method has the same problem.
It is thought that ideal reference samples for the pro-
gram would show moderate variance of the gene expres-
sion level. Although cancer cell lines and healthy cells
from the same organ were used in this research, further
examination is necessary to assess whether this is the
best choice. In addition, parameter optimization (degree
of rank change, standard deviation and so on) for the
reference samples is required.
The following points are limitations of this method,
and alternative methods are needed. As this method de-
tects the intragenic expression change in fusion partner
genes, the method cannot detect the genes with no sig-
nificant expression change between exons. Additionally,
breakpoint detection from exon array data depends on
the genomic position of the probe set. Thus, this methodis not able to identify breakpoints on genomic DNA in
detail.
Contribution of the fusion genes to cancer
The discovery of fusion genes that contribute to the
pathology (tumorigenesis, metastasis etc.) are hoped
from the viewpoint of the diagnosis and treatment of
cancer. Considering the functional aspect of the fusion
gene, it is important to incorporate other information,
such as protein domain composition, when prioritizing
novel, biologically relevant genomic aberrations [25].
Although three novel fusion genes were identified in
this research, their function and contribution to cancer
are unclear.
DOCK5-CDCA2:
DOCK5 (dedicator of cytokinesis 5) is a member of the
DOCK family of guanine nucleotide exchange factors
which function as activators of small G proteins [26]. Al-
though DOCK5 is predicted to activate the small G
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ties are poorly understood. CDCA2 (cell division cycle
associated 2) recruits protein phosphatase 1 to mitotic
chromatin at anaphase and into the following interphase,
regulating the chromosome structure during mitosis
[27]. Because DOCK5 and CDCA2 show out-of-frame
fusion, it is thought that the amino acid sequence of
CDCA2 is disrupted and a premature termination codon
appears in CDCA2 exon 14. The fusion gene might
therefore produce a short protein, 42aa (14aa from
DOCK5 exon 1, and 28aa from CDCA2 exon 14). No
functional protein domains have been found so the func-
tion of the fusion protein is unclear. Significant chromo-
some loss and underexpression of DOCK5 have been
reported in osteosarcoma [28]. DOCK5 dysfunction might
contribute to tumors.
ZMYND8-CEP250:
ZMYND8 is a member of RACK (receptor for activated
C-kinase) family proteins that anchor activated protein
kinase C (PKC). ZMYND8 interacts specifically with
PKCβI and is predicted to regulate subcellular localization
and activity [29]. In addition, ZMYND8 contains a bromo
domain, a PWWP domain, and two zinc fingers, and is
thought to be a transcriptional regulator. CEP250 is a core
centrosomal protein required for centriole-centriole cohe-
sion during interphase of the cell cycle [30], but details of
the mechanism are not well known. ZMYND8-CEP250 is
also an out-of-frame fusion gene, so a premature termin-
ation codon appears in CEP250 exon 24 and is likely to
express a 1121aa protein (994aa from ZMYND8 exon 1–
19, and 127aa from CEP250 exon 22–24). The down-
regulation of PKCβ1 protein expression has been reported
in colon cancer [31]. The PKCβ1 binding site in the C ter-
minal region of ZMYND8 racks in the predicted fusion
protein. Formation of the fusion gene may lead to the low
activity of PKCB1, and may contribute to cancer, or de-
regulation of the transcript regulatory network managed by
ZMYND8 might cause cancer.
RLF-ZMPSTE24:
RLF is predicted as a transcription factor with zinc fin-
gers from the amino acid sequence. It is reported that
RLF forms a fusion gene with the LMYC gene in lung
cancer [32]. The fusion gene RLF-LMYC contributes to
carcinogenesis by changing the LMYC manifestation of
a gene [33]. ZMPSTE24 performs a critical endoproteo-
lytic cleavage step to generate mature lamin A, a major
component of the nuclear lamina and nuclear skeleton
[34]. Lack of functional ZMPSTE24 results in progeroid
phenotypes, including genomic instability in mice and
humans [35,36]. RLF-ZMPSTE24 is an in-frame fusion
gene, which may expresses the 704aa protein (270aa
from RLF exon 1–5, and 434aa from ZMPSTE24 exon2–10). The known function domains of RLF are not con-
tained in the fusion gene, and no change of ZMPSTE24
expression level is observed in Exon Array data. Func-
tional change of ZMPSTE24 may induce DNA damage
and lead to cancer.
Genomic structure of the fusion genes
RLF and ZMPSTE24 genes located on chromosome 1,
approximately 20 kb apart, have the same orientation.
Southern blot analysis with a probe hybridizing to RLF in-
tron 5 region showed chromosome rearrangement (data
not shown), and a fragment that is part of RLF intron 5
fused to a part of ZMPSTE24 intron 1 was obtained by
TAIL-PCR for the upstream region of ZMPSTE24 exon 2
on genomic DNA (data not shown). Both parts fused in the
opposite orientation; therefore, the cause of the gene fusion,
RLF-ZMPSTE24, might be chromosome inversion with
some deletion. ZMYND8 and CEP250 genes were located
on chromosome 20, approximately 12 Mb apart, in oppos-
ite orientation. DOCK5 and CDCA2 genes were located on
chromosome 8, approximately 50Kb apart, in the same
orientation. The mechanisms of gene fusions remain to be
revealed.
The proposed method might be applied to not only
Exon Array but also the Affymetrx GeneChip Gene 1.0
ST Array (Gene Array) with some improvements. Gene
Array, in which each of the 28,869 genes is represented
on the array by approximately 26 probes spread along
the full length of the gene, is widely used for global gene
expression analysis. Using this method for more sam-
ples, it is thought that fusion genes can be identified.
This is expected to lead to new diagnostic methods and
treatment strategies.
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